<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1452" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1452/" /><meta name="ncbi_pagename" content="Retinoblastoma - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Retinoblastoma - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Retinoblastoma" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/11/21" /><meta name="citation_author" content="Dietmar R Lohmann" /><meta name="citation_author" content="Brenda L Gallie" /><meta name="citation_pmid" content="20301625" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1452/" /><meta name="citation_keywords" content="Retinoblastoma-associated protein" /><meta name="citation_keywords" content="RB1" /><meta name="citation_keywords" content="Retinoblastoma" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Retinoblastoma" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Dietmar R Lohmann" /><meta name="DC.Contributor" content="Brenda L Gallie" /><meta name="DC.Date" content="2018/11/21" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1452/" /><meta name="description" content="Retinoblastoma is a malignant tumor of the developing retina that occurs in children, usually before age five years. Retinoblastoma develops from cells that have cancer-predisposing variants in both copies of RB1. Retinoblastoma may be unifocal or multifocal. About 60% of affected individuals have unilateral retinoblastoma with a mean age of diagnosis of 24 months; about 40% have bilateral retinoblastoma with a mean age of diagnosis of 15 months. Heritable retinoblastoma is an autosomal dominant susceptibility for retinoblastoma. Individuals with heritable retinoblastoma are also at increased risk of developing non-ocular tumors." /><meta name="og:title" content="Retinoblastoma" /><meta name="og:type" content="book" /><meta name="og:description" content="Retinoblastoma is a malignant tumor of the developing retina that occurs in children, usually before age five years. Retinoblastoma develops from cells that have cancer-predisposing variants in both copies of RB1. Retinoblastoma may be unifocal or multifocal. About 60% of affected individuals have unilateral retinoblastoma with a mean age of diagnosis of 24 months; about 40% have bilateral retinoblastoma with a mean age of diagnosis of 15 months. Heritable retinoblastoma is an autosomal dominant susceptibility for retinoblastoma. Individuals with heritable retinoblastoma are also at increased risk of developing non-ocular tumors." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1452/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/retinoblastoma/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1452/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A0D26E0404AA10000000007360292.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1452_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1452_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/rvcl/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/rtps/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1452_"><span class="title" itemprop="name">Retinoblastoma</span></h1><p class="contrib-group"><span itemprop="author">Dietmar R Lohmann</span>, MD and <span itemprop="author">Brenda L Gallie</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1452_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1452_ai__"><div class="contrib half_rhythm"><span itemprop="author">Dietmar R Lohmann</span>, MD<div class="affiliation small">Professor, Eye Oncogenetics Research Group<br />Institute of Human Genetics<br />University Hospital Essen<br />Essen, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.eud-inu@nnamhol.ramteid" class="oemail">ed.eud-inu@nnamhol.ramteid</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Brenda L Gallie</span>, MD<div class="affiliation small">Professor, University of Toronto<br />Head, Retinoblastoma Program<br />Hospital for Sick Children<br />Toronto, Ontario, Canada<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ac.eillag@adnerb" class="oemail">ac.eillag@adnerb</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 18, 2000</span>; Last Update: <span itemprop="dateModified">November 21, 2018</span>.</p><p><em>Estimated reading time: 27 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="retinoblastoma.Summary" itemprop="description"><h2 id="_retinoblastoma_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Retinoblastoma is a malignant tumor of the developing retina that occurs in children, usually before age five years. Retinoblastoma develops from cells that have cancer-predisposing variants in both copies of <i>RB1</i>. Retinoblastoma may be unifocal or multifocal. About 60% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have unilateral retinoblastoma with a mean age of diagnosis of 24 months; about 40% have bilateral retinoblastoma with a mean age of diagnosis of 15 months. Heritable retinoblastoma is an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> susceptibility for retinoblastoma. Individuals with heritable retinoblastoma are also at increased risk of developing non-ocular tumors.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of retinoblastoma is usually established by examination of the fundus of the eye using indirect ophthalmoscopy. Imaging studies can be used to support the diagnosis and stage the tumor. The diagnosis of heritable retinoblastoma is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with retinoblastoma or retinoma and a family history of retinoblastoma or by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>RB1.</i></p><p>The following staging has been recommended for individuals with retinoblastoma and/or risk of heritable retinoblastoma to include "H" to describe the genetic risk for an individual to have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>RB1</i>:</p><ul><li class="half_rhythm"><div>HX. Unknown or insufficient evidence of a constitutional (<a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>) <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></div></li><li class="half_rhythm"><div>H0. Normal <i>RB1</i> alleles in blood tested with demonstrated high-<a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> assays</div></li><li class="half_rhythm"><div>[H0*. Normal <i>RB1</i> in blood with &#x0003c;1% residual risk for <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a>]</div></li><li class="half_rhythm"><div>H1. Bilateral retinoblastoma, trilateral retinoblastoma (retinoblastoma with intracranial CNS midline embryonic tumor), family history of retinoblastoma, or <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in blood</div></li></ul></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Early diagnosis and treatment of retinoblastoma and non-ocular tumors can reduce morbidity and increase longevity; care is best provided by multidisciplinary teams of specialists including ophthalmology, pediatric oncology, pathology, and radiation oncology. Treatment options depend on tumor stage, number of tumor foci (unifocal, unilateral multifocal, or bilateral), localization and size of the tumor(s) within the eye(s), presence of vitreous seeding, the potential for useful vision, the extent and kind of extraocular extension, and the resources available. Treatment options include enucleation; cryotherapy; laser, systemic, or local ocular chemotherapy including intra-arterial chemotherapy, combined with or followed by laser or cryotherapy; radiation therapy using episcleral plaques; and, as a last resort, external beam radiotherapy.</p><p><i>Prevention of secondary manifestations:</i> If possible, radiation (including x-ray, CT scan, and external beam radiation) should be avoided in H1 individuals with heritable retinoblastoma to minimize the lifetime risk of developing late-onset second cancers.</p><p><i>Surveillance:</i> Children known to have an <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (H1) have eye examination under anesthesia every three to four weeks until age six months, then less frequently until age three years, in order to identify retinoblastoma tumors as early and small as possible. Clinical examinations with cooperative children are performed every three to six months until age seven years, then annually and eventually biennially for life. Individuals who have unilateral retinoblastoma without an identified <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> germline <i>RB1</i> pathogenic variant (H0*) are still at risk for low-level <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> and should have regular clinical examination of the eyes, including clinical ultrasound. Individuals with retinomas are followed with retinal examinations and imaging every one to two years. To detect second non-ocular tumors in H1 individuals with retinoblastoma, physicians and parents should promptly evaluate complaints of bone pain or lumps because of the high risk for sarcomas and other cancers; however, effective screening protocols have not yet been developed.</p><p><i>Agents/circumstances to avoid:</i> Limiting exposure to DNA-damaging agents (radiation, tobacco, and UV light) may reduce the excess cancer risks in H1 survivors of heritable retinoblastoma.</p><p><i>Evaluation of relatives at risk:</i> Molecular genetic testing for early identification of asymptomatic at-risk children in a family reduces the need for costly screening procedures in those family members who have not inherited the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (i.e., H0).</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Heritable retinoblastoma is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Individuals with heritable retinoblastoma (H1) have a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> or inherited <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Offspring of H1 individuals have a 50% chance of inheriting the pathogenic variant. Prenatal testing for pregnancies at increased risk is possible if the <i>RB1</i> pathogenic variant has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member.</p></div></div><div id="retinoblastoma.Diagnosis"><h2 id="_retinoblastoma_Diagnosis_">Diagnosis</h2><p>Guidelines for diagnosis and care of children and families <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by retinoblastoma have been published [<a class="bk_pop" href="#retinoblastoma.REF3">Canadian Retinoblastoma Society 2009</a>] (<a href="https://www.canadianjournalofophthalmology.ca/article/S0008-4182(09)80179-8/pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><div id="retinoblastoma.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Retinoblastoma <b>should be suspected</b> in children with any of the following:</p><ul><li class="half_rhythm"><div>Leukocoria (white pupil)</div></li><li class="half_rhythm"><div>Strabismus</div></li><li class="half_rhythm"><div>Change in eye appearance</div></li><li class="half_rhythm"><div>Reduced visual acuity</div></li></ul><p><b>Heritable retinoblastoma</b>
<b>should be suspected</b> in an individual with any of the following:</p><ul><li class="half_rhythm"><div>A diagnosis of retinoblastoma, including unilateral (unifocal and multifocal) and bilateral involvement</div></li><li class="half_rhythm"><div>A retinoma</div></li><li class="half_rhythm"><div>A family history of retinoblastoma</div></li></ul></div><div id="retinoblastoma.Establishing_the_Diagnosi"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <b>retinoblastoma is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by retinal examination with full pupillary dilation by an ophthalmologist or optometrist. Confirmation of the diagnosis and determination of the disease extent is accomplished by examination under anesthesia. Ocular imaging can help confirm the diagnosis. Pathology is not required. Note: Biopsy may cause the tumor to spread beyond the eye, endangering the life of the individual.</p><p>The diagnosis of <b>heritable retinoblastoma is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with retinoblastoma or retinoma and a family history of retinoblastoma. However, the majority of individuals with retinoblastoma do not have a family history of the disorder. These patients require identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1452/table/retinoblastoma.T.molecular_genetic_testi/?report=objectonly" target="object" rid-figpopup="figretinoblastomaTmoleculargenetictesti" rid-ob="figobretinoblastomaTmoleculargenetictesti">Table 1</a>) to determine if the retinoblastoma is heritable. Identification of an <i>RB1</i> pathogenic variant in the proband allows for early diagnosis and screening for relatives at risk for retinoblastoma.</p><p>The following staging has been recommended to clarify genetic risk of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#retinoblastoma.REF.mallipatna.2017">Mallipatna et al 2017</a>, <a class="bk_pop" href="#retinoblastoma.REF.soliman.2017a.197">Soliman et al 2017a</a>]:</p><ul><li class="half_rhythm"><div><b>HX.</b> Individual with unknown or insufficient evidence of a constitutional (<a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>) <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></div></li><li class="half_rhythm"><div><b>H0.</b> Individual who did not inherit a known <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> confirmed by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a></div></li><li class="half_rhythm"><div>[<b>H0*.</b> Individual with retinoblastoma or retinoma with no <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>; residual risk of <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> is &#x0003c;1%.]</div></li><li class="half_rhythm"><div><b>H1.</b> Individual with bilateral retinoblastoma, trilateral retinoblastoma (retinoblastoma with intracranial CNS midline embryonic tumor), retinoblastoma and a family history of retinoblastoma, or identification of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a></div></li></ul><p>Molecular genetic testing approaches to identify individuals with <b>heritable retinoblastoma</b> can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and <b><a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA)</b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></p><ul><li class="half_rhythm"><div><b>Individuals with bilateral, unilateral <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a>, or unilateral multifocal retinoblastoma.</b> Sequence analysis and <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>RB1</i> are performed on peripheral blood DNA. Note: Targeted analysis for recurrent pathogenic variants may be offered by some laboratories (see <a class="figpopup" href="/books/NBK1452/table/retinoblastoma.T.molecular_genetic_testi/?report=objectonly" target="object" rid-figpopup="figretinoblastomaTmoleculargenetictesti" rid-ob="figobretinoblastomaTmoleculargenetictesti">Table 1</a>).</div></li><li class="half_rhythm"><div><b>Individuals with unilateral unifocal retinoblastoma and a negative family history</b></div><ul><li class="half_rhythm"><div>If tumor tissue is not available, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>RB1</i> are performed on peripheral blood DNA.</div></li><li class="half_rhythm"><div>If tumor tissue is available, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> and <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>RB1</i> are performed on tumor DNA. If pathogenic variants are identified, DNA from blood is tested for the presence of these variants. If no pathogenic variants are identified, <a class="def" href="/books/n/gene/glossary/def-item/methylation-analysis/">methylation analysis</a> of the <i>RB1</i> promoter CpG island is performed to identify epigenetic inactivation of <i>RB1</i> due to hypermethylation of the <i>RB1</i> promoter. If no hypermethylation is identified at the promoter, DNA from tumor is tested for the amplification of <i>MYCN</i>, which is the cause of retinoblastoma in the absence of <i>RB1</i> pathogenic variants in about 1.5% of individuals with <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> unilateral retinoblastoma.</div></li></ul></li></ul><p><b>CMA</b> uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications (including <i>RB1</i>) that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>. CMA may be considered in individuals with retinoblastoma associated with developmental delay and/or other <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> anomalies [<a class="bk_pop" href="#retinoblastoma.REF.mitter.2011.947">Mitter et al 2011</a>, <a class="bk_pop" href="#retinoblastoma.REF.cast_ra.2013.460">Cast&#x000e9;ra et al 2013</a>].</p><div id="retinoblastoma.T.molecular_genetic_testi" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Heritable Retinoblastoma</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1452/table/retinoblastoma.T.molecular_genetic_testi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__retinoblastoma.T.molecular_genetic_testi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sample</th><th id="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Germline Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>RB1</i></td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Germline, tumor</td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">80%-84%</td></tr><tr><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Germline, tumor</td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16%-20%</td></tr><tr><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">CMA&#x000a0;<sup>5</sup></td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Germline</td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6%-8%&#x000a0;<sup>6</sup></td></tr><tr><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants</td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Germline, tumor</td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">25%&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Methylation analysis</td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Tumor</td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 8</td></tr><tr><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Allele loss analysis</td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Tumor</td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 9</td></tr><tr><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>MYCN</i></td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Tumor</td><td headers="hd_h_retinoblastoma.T.molecular_genetic_testi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 10</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="retinoblastoma.TF.1.1"><p class="no_margin">See <a href="/books/NBK1452/#retinoblastoma.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="retinoblastoma.TF.1.2"><p class="no_margin">See <a href="#retinoblastoma.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="retinoblastoma.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="retinoblastoma.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications. Gene-targeted deletion/duplication testing will detect deletions ranging from a single exon to the whole gene; however, breakpoints of large deletions and/or deletion of adjacent genes (e.g., those described by <a class="bk_pop" href="#retinoblastoma.REF.mitter.2011.947">Mitter et al [2011]</a>, <a class="bk_pop" href="#retinoblastoma.REF.cast_ra.2013.460">Cast&#x000e9;ra et al [2013]</a>) may not be detected by these methods.</p></div></dd><dt>5. </dt><dd><div id="retinoblastoma.TF.1.5"><p class="no_margin">Chromosomal microarray analysis (CMA) uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications (including <i>RB1</i>) that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>. The ability to determine the size of the <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> depends on the type of microarray used and the density of probes in the 13q14 region. CMA designs in current clinical use target the 13q14 region.</p></div></dd><dt>6. </dt><dd><div id="retinoblastoma.TF.1.6"><p class="no_margin">Approximately 6%-8% of individuals with retinoblastoma have a <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of 13q14. Such chromosome abnormalities are often associated with developmental delay and birth defects [<a class="bk_pop" href="#retinoblastoma.REF.mitter.2011.947">Mitter et al 2011</a>; <a class="bk_pop" href="#retinoblastoma.REF.cast_ra.2013.460">Cast&#x000e9;ra et al 2013</a>; Author, unpublished data].</p></div></dd><dt>7. </dt><dd><div id="retinoblastoma.TF.1.7"><p class="no_margin">Pathogenic variants that result in premature termination due to CpG-transitions account for 25% of all <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants [<a class="bk_pop" href="#retinoblastoma.REF.rushlow.2009.842">Rushlow et al 2009</a>; Author, unpublished data].</p></div></dd><dt>8. </dt><dd><div id="retinoblastoma.TF.1.8"><p class="no_margin">Hypermethylation of <i>RB1</i> promoter (which silences <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> expression) is observed in approximately 15% of tumors from individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a>, unilateral retinoblastoma [<a class="bk_pop" href="#retinoblastoma.REF.zeschnigk.2004.e125">Zeschnigk et al 2004</a>; Author, unpublished data]. In these individuals, analysis of the promoter <a class="def" href="/books/n/gene/glossary/def-item/methylation/">methylation</a> status in DNA from tumor is needed to identify the two inactive <i>RB1</i> alleles that triggered tumor development.</p></div></dd><dt>9. </dt><dd><div id="retinoblastoma.TF.1.9"><p class="no_margin">Testing for <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a> in tumors. Comparative <a class="def" href="/books/n/gene/glossary/def-item/genotyping/">genotyping</a> of polymorphic loci within and flanking <i>RB1</i> in DNA from peripheral blood and tumor can reveal that loss of the normal <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (hemizygosity) with or without <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> (homozygosity) of the mutated allele constitutes the <a class="def" href="/books/n/gene/glossary/def-item/somatic-pathogenic-variant/">somatic pathogenic variant</a>. Observed in 60%-70% of tumors from patients with <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> unilateral retinoblastoma.</p></div></dd><dt>10. </dt><dd><div id="retinoblastoma.TF.1.10"><p class="no_margin">About 1.5% of children with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> unilateral retinoblastoma have high-level <i>MYCN</i> amplification on tumor tissue testing but no pathogenic variants leading to inactivation of <i>RB1</i> [<a class="bk_pop" href="#retinoblastoma.REF.rushlow.2013.327">Rushlow et al 2013</a>]. The genetic interpretation of high-level <i>MYCN</i> amplification in the context of routine genetic testing is not yet established.</p></div></dd></dl></div></div></div><div id="retinoblastoma.T.probability_of_a_germli" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Probability of a Germline Pathogenic Variant Being Present in a Proband with Retinoblastoma Based on Family History and Tumor Presentation</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1452/table/retinoblastoma.T.probability_of_a_germli/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__retinoblastoma.T.probability_of_a_germli_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_1" rowspan="3" scope="col" colspan="1" headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_1" style="text-align:left;vertical-align:middle;">Family History</th><th id="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2" colspan="3" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Retinoblastoma Presentation</th><th id="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_3" rowspan="3" scope="col" colspan="1" headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_3" style="text-align:left;vertical-align:middle;">Probability That an <i>RB1</i> Germline Pathogenic Variant Is Present</th></tr><tr><th headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2" id="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Unilateral</th><th headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_2" id="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_2" rowspan="2" scope="col" colspan="1" style="text-align:center;vertical-align:middle;">Bilateral</th></tr><tr><th headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1" id="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Multifocal</th><th headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1" id="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unifocal</th></tr></thead><tbody><tr><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Positive&#x000a0;<sup>1</sup></b></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">+</td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr><tr><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_1" colspan="1" scope="row" rowspan="1" style="text-align:center;vertical-align:middle;">+</td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr><tr><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">+</td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">100%</td></tr><tr><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Negative&#x000a0;<sup>2</sup></b></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">+</td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Close to 100%&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_1" colspan="1" scope="row" rowspan="1" style="text-align:center;vertical-align:middle;">+</td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">14%-95%</td></tr><tr><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_1 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_3_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">+</td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_2 hd_h_retinoblastoma.T.probability_of_a_germli_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.probability_of_a_germli_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~14%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="retinoblastoma.TF.2.1"><p class="no_margin">Positive = more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member (10% of retinoblastoma)</p></div></dd><dt>2. </dt><dd><div id="retinoblastoma.TF.2.2"><p class="no_margin">Negative = only one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in the family (90% of retinoblastoma)</p></div></dd><dt>3. </dt><dd><div id="retinoblastoma.TF.2.3"><p class="no_margin"><i>RB1</i> pathogenic variants are identified by conventional molecular testing in 90%-97% of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases with bilateral involvement; the remaining 5% may have translocations, deep <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> splice variants, or low-level mosaic pathogenic variants that may or may not be in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>.</p></div></dd></dl></div></div></div><p>Note: (1) If neither <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in tumor tissue is found in the DNA of non-tumor cells (constitutional DNA), the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a low probability of having an <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variant. (2) Because blood <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> as low as 20% can usually be detected by conventional molecular analysis such as sequencing, the failure to detect an <i>RB1</i> pathogenic variant in constitutional DNA reduces but cannot eliminate the probability that the individual has an <i>RB1</i> pathogenic variant in his/her germline.</p></div></div><div id="retinoblastoma.Clinical_Characteristics"><h2 id="_retinoblastoma_Clinical_Characteristics_">Clinical Characteristics</h2><div id="retinoblastoma.Clinical_Description"><h3>Clinical Description</h3><p><b>Retinoblastoma.</b> The most common presenting sign is a white pupillary reflex (leukocoria). Strabismus is the second most common presenting sign and may accompany or precede leukocoria [<a class="bk_pop" href="#retinoblastoma.REF.abramson.2003.1248">Abramson et al 2003</a>]. Unusual presenting signs include glaucoma, orbital cellulitis, uveitis, hyphema, or vitreous hemorrhage. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children are diagnosed before age five years. Atypical manifestations are more frequent in older children.</p><p>Probands with retinoblastoma usually present in one of the following clinical settings:</p><ul><li class="half_rhythm"><div>Negative family history and unilateral retinoblastoma (60% of probands)</div></li><li class="half_rhythm"><div>Negative family history and bilateral retinoblastoma (30% of probands)</div></li><li class="half_rhythm"><div>Positive family history and unilateral or bilateral retinoblastoma (~10% of probands). For H1 individuals (see <a href="#retinoblastoma.Establishing_the_Diagnosi">Establishing the Diagnosis</a>) with a positive family history who undergo clinical surveillance via serial retinal examinations, tumors are often identified in the first month of life.</div></li><li class="half_rhythm"><div>Chromosome <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> involving band 13q14. Up to 5% of all index cases with unifocal retinoblastoma and 7.5% of all index cases with multifocal retinoblastoma have a <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> deletion of 13q14. Such chromosome abnormalities are often associated with developmental delay and birth defects [<a class="bk_pop" href="#retinoblastoma.REF.mitter.2011.947">Mitter et al 2011</a>, <a class="bk_pop" href="#retinoblastoma.REF.cast_ra.2013.460">Cast&#x000e9;ra et al 2013</a>].</div></li></ul><p>Retinoblastoma is:</p><ul><li class="half_rhythm"><div><b>Unilateral</b> if only one eye is affected by retinoblastoma. About 60% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have unilateral retinoblastoma with a mean age at diagnosis of 24 months. Usually, in individuals with unilateral retinoblastoma the tumor is also unifocal (i.e., only a single tumor is present). Some individuals have multifocal tumors in one eye (unilateral multifocal retinoblastoma). Intraocular seeding may mimic primary multifocal tumor growth. In most persons with unilateral retinoblastoma without a family history, the tumor is large and it is not possible to determine if a single tumor is present.</div></li><li class="half_rhythm"><div><b>Bilateral</b> if both eyes are affected by retinoblastoma. About 40% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have bilateral retinoblastoma with a mean age at diagnosis of 15 months. In most children with bilateral tumors, both eyes are affected at the time of initial diagnosis. In individuals with bilateral retinoblastoma both eyes may show multiple tumors. Some children who are initially diagnosed with unilateral retinoblastoma later develop a tumor in the contralateral unaffected eye.</div></li><li class="half_rhythm"><div><b>Trilateral</b> if bilateral (or, rarely, unilateral) retinoblastoma and a pinealoblastoma develop (see <b>Pinealoblastomas</b>).</div></li></ul><p><b>Retinoma and associated eye lesions.</b> Benign retinal tumors (called retinoma) that have undergone spontaneous growth arrest may present within retinal scars [<a class="bk_pop" href="#retinoblastoma.REF.dimaras.2008.1363">Dimaras et al 2008</a>]. Calcified phthisic eyes may result from spontaneous regression of retinoblastoma associated with vascular occlusion [<a class="bk_pop" href="#retinoblastoma.REF.valverde.2002.277">Valverde et al 2002</a>]. The spectrum of <i>RB1</i> pathogenic variants in individuals with retinoma and a family history for retinoblastoma and individuals who had retinoma in one eye and either retinoma or retinoblastoma in the other eye appears to be indistinct from that of individuals with bilateral retinoblastoma [<a class="bk_pop" href="#retinoblastoma.REF.abouzeid.2009.771">Abouzeid et al 2009</a>].</p><p><b>Pinealoblastomas</b> occur in "retina-like" tissue in the pineal gland of the brain. Concurrence of pinealoblastomas or primitive neuroectodermal tumors and retinoblastoma is referred to as trilateral retinoblastoma. Pinealoblastoma is rare and usually fatal, unlike retinoblastoma of the eye, which is generally curable [<a class="bk_pop" href="#retinoblastoma.REF.de_jong.2014.1157">de Jong et al 2014</a>].</p><p><b>Other tumors.</b> There is an increased risk for other specific extraocular primary neoplasms (collectively called second primary tumors). Most of the second primary tumors are osteosarcomas, soft tissue sarcomas (mostly leiomyosarcomas and rhabdomyosarcomas), or melanomas [<a class="bk_pop" href="#retinoblastoma.REF.kleinerman.2007.24">Kleinerman et al 2007</a>, <a class="bk_pop" href="#retinoblastoma.REF.marees.2008.1771">Marees et al 2008</a>, <a class="bk_pop" href="#retinoblastoma.REF.kleinerman.2012.950">Kleinerman et al 2012</a>]. These tumors usually manifest in adolescence or adulthood. The incidence of second primary tumors is increased to more than 50% in individuals with retinoblastoma who have received external beam radiation therapy [<a class="bk_pop" href="#retinoblastoma.REF.wong.1997.1262">Wong et al 1997</a>]. Survivors of heritable retinoblastoma who are not exposed to high-dose radiotherapy also have a high lifetime risk of developing a late-onset cancer [<a class="bk_pop" href="#retinoblastoma.REF.dommering.2012b.225">Dommering et al 2012b</a>, <a class="bk_pop" href="#retinoblastoma.REF.kleinerman.2012.950">Kleinerman et al 2012</a>, <a class="bk_pop" href="#retinoblastoma.REF.maccarthy.2013.2455">MacCarthy et al 2013</a>, <a class="bk_pop" href="#retinoblastoma.REF.temming.2015.1799">Temming et al 2015</a>].</p></div><div id="retinoblastoma.GenotypePhenotype_Correla"><h3>Genotype-Phenotype Correlations</h3><p>In the majority of families with heritable retinoblastoma, all members who have inherited the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> develop multiple tumors in both eyes. It is not unusual to find, however, that the founder (i.e., the first person in the family to have retinoblastoma) has only unilateral retinoblastoma. Most of these families segregate <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> alleles that are altered by frameshift or <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants. With few exceptions, <i>RB1</i> null alleles show nearly complete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> (&#x0003e;99%) [<a class="bk_pop" href="#retinoblastoma.REF.taylor.2007.284">Taylor et al 2007</a>, <a class="bk_pop" href="#retinoblastoma.REF.dommering.2014.366">Dommering et al 2014</a>, <a class="bk_pop" href="#retinoblastoma.REF.frenkel.2016.313">Frenkel et al 2016</a>].</p><p>Fewer than 10% of families show a "low-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>" <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> with reduced expressivity (i.e., increased prevalence of unilateral retinoblastoma) and incomplete penetrance (i.e., &#x02264;25%). This low-penetrance phenotype is usually associated with <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a>, <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, or distinct <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants, certain <a class="def" href="/books/n/gene/glossary/def-item/indel/">indel</a> variants in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1, or pathogenic variants in the <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a>.</p><p>A third category of families shows differential <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> depending on the parental origin of the pathogenic <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> (parent-of-origin effect) [<a class="bk_pop" href="#retinoblastoma.REF.klutz.2002.174">Klutz et al 2002</a>, <a class="bk_pop" href="#retinoblastoma.REF.eloy.2016.e1005888">Eloy et al 2016</a>, <a class="bk_pop" href="#retinoblastoma.REF.imperatore.2018.1026">Imperatore et al 2018</a>].</p><p>Cytogenetically visible deletions involving 13q14 that also result in deletions of additional genes in the same <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> region as <i>RB1</i> may cause developmental delay [<a class="bk_pop" href="#retinoblastoma.REF.cast_ra.2013.460">Cast&#x000e9;ra et al 2013</a>] and mild-to-moderate facial dysmorphism. As sizeable deletions of 13q14 show reduced expressivity, a considerable proportion of individuals with such deletions show unilateral retinoblastoma only; some of these children do not develop any tumors [<a class="bk_pop" href="#retinoblastoma.REF.mitter.2011.947">Mitter et al 2011</a>]. Contiguous loss of <i>MED4</i>, which is located centromeric to <i>RB1</i>, explains reduced expressivity in individuals with large deletions that include both <i>RB1</i> and <i>MED4</i> [<a class="bk_pop" href="#retinoblastoma.REF.dehainault.2014.5243">Dehainault et al 2014</a>].</p></div><div id="retinoblastoma.Penetrance"><h3>Penetrance</h3><p>See <a href="#retinoblastoma.GenotypePhenotype_Correla">Genotype-Phenotype Correlations</a>.</p></div><div id="retinoblastoma.Nomenclature"><h3>Nomenclature</h3><p>Glioma retinae is a historical name for retinoblastoma.</p></div><div id="retinoblastoma.Prevalence"><h3>Prevalence</h3><p>The incidence of retinoblastoma is estimated at between 1:15,000 and 1:20,000 live births [<a class="bk_pop" href="#retinoblastoma.REF.moll.1997.559">Moll et al 1997</a>, <a class="bk_pop" href="#retinoblastoma.REF.seregard.2004.1228">Seregard et al 2004</a>].</p></div></div><div id="retinoblastoma.Genetically_Related_Allel"><h2 id="_retinoblastoma_Genetically_Related_Allel_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>RB1</i>.</p><p>Sporadic tumors including bladder urothelial cancer, uterine endometrial cancer, sarcoma, squamous cell cancer of the lung, and lung adenocarcinoma (<a href="https://portal.gdc.cancer.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">portal.gdc.cancer.gov</a>) occurring as single tumors in the absence of any other findings of heritable retinoblastoma frequently harbor somatic variants in <i>RB1</i> that are <b>not</b> present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>. In these circumstances predisposition to these tumors is not heritable.</p></div><div id="retinoblastoma.Differential_Diagnosis"><h2 id="_retinoblastoma_Differential_Diagnosis_">Differential Diagnosis</h2><p>Several ocular conditions of childhood can clinically simulate retinoblastoma:</p><ul><li class="half_rhythm"><div>Sporadic <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> disorders including persistent hyperplastic primary vitreous and Coats disease (see <a href="/books/n/gene/norrie/"><i>NDP</i>-Related Retinopathies</a>)</div></li><li class="half_rhythm"><div>Hereditary disorders including <a href="/books/n/gene/tuberous-sclerosis/">tuberous sclerosis complex</a>, <a href="/books/n/gene/norrie/">Norrie disease</a>, <a href="/books/n/gene/i-p/">incontinentia pigmenti</a>, <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> exudative vitreoretinopathy (see <a href="/books/n/gene/fevr/">Autosomal Dominant Familial Exudative Vitreoretinopathy</a>), and <a href="/books/n/gene/vhl/">von Hippel-Lindau syndrome</a></div></li><li class="half_rhythm"><div>Ocular infestation by <i>Toxocara canis</i></div></li></ul></div><div id="retinoblastoma.Management"><h2 id="_retinoblastoma_Management_">Management</h2><p>Guidelines for retinoblastoma care have been developed [<a class="bk_pop" href="#retinoblastoma.REF3">Canadian Retinoblastoma Society 2009</a>] (<a href="https://www.canadianjournalofophthalmology.ca/article/S0008-4182(09)80179-8/pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><div id="retinoblastoma.Evaluations_Following_Ini"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with retinoblastoma, the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Prior to planning therapy, the extent of the tumor within and outside the eye should be determined. Each <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> eye is assigned a cancer stage, depending on the extent of disease and the risk that the cancer has spread outside the eye [<a class="bk_pop" href="#retinoblastoma.REF.mallipatna.2017">Mallipatna et al 2017</a>]. Extent of the tumor is estimated by clinical examination under anesthetic and ultrasound or MRI, particularly focusing on the tumor - optic nerve relationship. Brain MRI is also useful to evaluate for a pinealoblastoma, indicating trilateral retinoblastoma. CT examination is NOT recommended because of the increased risk for second primary cancer potentially induced by radiation.</div></li><li class="half_rhythm"><div>For very large tumors with risk factors for extraocular disease, bone marrow aspiration and examination of cerebrospinal fluid may also be performed at diagnosis, or performed when pathologic examination of the enucleated eye reveals optic nerve invasion or significant risks for extraocular extension.</div></li><li class="half_rhythm"><div>If retinoblastoma has spread outside the eye, the stage of cancer will be evaluated to determine the most appropriate care of the child.</div></li><li class="half_rhythm"><div>In individuals with a family history of retinoblastoma, and in uncommon circumstances in which the child presents with strabismus or poor vision, the retinal tumors may be small and detected by optical coherent tomography [<a class="bk_pop" href="#retinoblastoma.REF.soliman.2017b.859">Soliman et al 2017b</a>].</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor is appropriate.</div></li></ul></div><div id="retinoblastoma.Treatment_of_Manifestatio"><h3>Treatment of Manifestations</h3><p>Goals of treatment in order of priority are preservation of life and then of sight. As optimal treatment may be complex, specialists skilled in the treatment of retinoblastoma from various fields including ophthalmology, pediatric oncology, pathology, and radiation oncology collaborate to deliver optimized care.</p><p>In addition to eye and tumor stage, choice of treatment depends on many factors, including the number of tumor foci (unifocal, unilateral multifocal, or bilateral), localization and size of the tumor(s) within the eye(s), presence of vitreous seeding, the potential for useful vision, the extent and kind of extraocular extension, and the resources available.</p><p>Treatment options for the eye include enucleation; cryotherapy; laser, systemic, or local ocular chemotherapy including intra-arterial chemotherapy, combined with or followed by laser or cryotherapy; radiation therapy using episcleral plaques; and, as a last resort, external beam radiotherapy.</p></div><div id="retinoblastoma.Prevention_of_Secondary_C"><h3>Prevention of Secondary Complications</h3><p>If possible, any radiation (including x-ray, CT scan, and external beam radiation) are avoided to minimize the lifetime risk of developing late-onset second cancers. Such tests should only be used if absolutely necessary in essential health care.</p></div><div id="retinoblastoma.Surveillance"><h3>Surveillance</h3><p>Further information regarding medical surveillance for those who have had or are at risk of developing retinoblastoma is available in the <a href="https://www.canadianjournalofophthalmology.ca/article/S0008-4182(09)80179-8/pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">guidelines for retinoblastoma care</a>. Guidelines for clinical screening for children at risk are published [<a class="bk_pop" href="#retinoblastoma.REF.skalet.2018.453">Skalet et al 2018</a>].</p><p><b>Detection of subsequent retinoblastoma after initial diagnosis.</b> Following successful treatment, children require frequent follow-up examination for early detection of newly arising intraocular tumors, as indicated in guidelines [<a class="bk_pop" href="#retinoblastoma.REF.skalet.2018.453">Skalet et al 2018</a>]:</p><ul><li class="half_rhythm"><div>It is recommended that children known to have an <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (H1) have an eye examination under anesthesia every three to four weeks until age six months, then less frequently until age three years. Clinical examinations with cooperative children are performed every three to six months until age seven years, then annually and eventually biennially for life.</div></li><li class="half_rhythm"><div>Individuals who have unilateral retinoblastoma without an identified <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are at risk for low-level <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> (H0*) and can develop a tumor in the other eye [<a class="bk_pop" href="#retinoblastoma.REF.temming.2013.475">Temming et al 2013</a>]. This risk is small enough that examination under anesthesia may be replaced with regular clinical examination of the eyes, including clinical ultrasound (a simple, noninvasive procedure).</div></li><li class="half_rhythm"><div>Individuals with retinomas (premalignant retinal lesions associated with retinoblastoma) are followed with retinal examinations and imaging every one to two years, to detect any change early.</div></li></ul><p><b>Detection of second non-ocular tumors in individuals with retinoblastoma.</b> Because of the high risk for second cancers, including sarcomas, melanoma, and specific other cancers, prompt investigation of any signs or symptoms is indicated. Total-body MRI at regular intervals is under investigation to determine when the technology will be specific and sensitive enough for screening for second cancers in persons with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="retinoblastoma.AgentsCircumstances_to_Av"><h3>Agents/Circumstances to Avoid</h3><p>It has been suggested by <a class="bk_pop" href="#retinoblastoma.REF.fletcher.2004.357">Fletcher et al [2004]</a> that cancer risks in survivors of heritable retinoblastoma may be reduced by limiting exposure to DNA-damaging agents (radiotherapy, tobacco, and UV light). It is plausible that cancer risks in these individuals may be reduced by limiting exposure to chemotherapy.</p></div><div id="retinoblastoma.Evaluation_of_Relatives_a"><h3>Evaluation of Relatives at Risk</h3><p>The American Society of Clinical Oncologists identifies heritable retinoblastoma as a Group 1 disorder &#x02013; i.e., a hereditary syndrome for which genetic testing is considered part of the standard management for at-risk family members [<a class="bk_pop" href="#retinoblastoma.REF2">American Society of Clinical Oncology 2003</a>]. It is appropriate to evaluate apparently asymptomatic <b>at-risk</b> relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from eye examination by an experienced ophthalmologist and allow for early identification of a retinoblastoma.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known, which reduces the need for costly screening procedures in those at-risk family members who have not inherited the pathogenic variant [<a class="bk_pop" href="#retinoblastoma.REF.noorani.1996.301">Noorani et al 1996</a>, <a class="bk_pop" href="#retinoblastoma.REF.richter.2003.253">Richter et al 2003</a>];</div></li><li class="half_rhythm"><div>Eye examinations by an ophthalmologist experienced in the treatment of retinoblastoma starting directly after birth as described above (see <a href="#retinoblastoma.Surveillance">Surveillance</a>, <b>Detection of subsequent retinoblastoma after initial diagnosis</b>. Young or uncooperative children may require examination under anesthesia.</div></li></ul><p>See <a href="#retinoblastoma.Related_Genetic_Counselin">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="retinoblastoma.Therapies_Under_Investiga"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There are not many clinical trials for this disorder.</p></div></div><div id="retinoblastoma.Genetic_Counseling"><h2 id="_retinoblastoma_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="retinoblastoma.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Heritable retinoblastoma is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="retinoblastoma.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Some individuals diagnosed with heritable retinoblastoma inherited an <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from a parent who may or may not be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div>In approximately 5% of probands with a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> who represent <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., a single <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in the family), one of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s unaffected parents also has the pathogenic variant. In most cases this is a mosaic or heterozygous "reduced-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>" pathogenic variant, such as a <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant [<a class="bk_pop" href="#retinoblastoma.REF.rushlow.2009.842">Rushlow et al 2009</a>, <a class="bk_pop" href="#retinoblastoma.REF.skalet.2018.453">Skalet et al 2018</a>].</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with heritable retinoblastoma may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The majority of individuals with heritable retinoblastoma and no family history of retinoblastoma have the disorder as the result of a <i>de novo</i> pathogenic variant.</div></li><li class="half_rhythm"><div>Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. If the <i>RB1</i> pathogenic variant in the proband is not known, recommendations for the evaluation of parents of a proband include examination by an ophthalmologist knowledgeable about retinoblastoma, retinoma, and retinoblastoma-associated eye lesions.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. The incidence of parental mosaicism detected by MLPA or <a class="def" href="/books/n/gene/glossary/def-item/sanger-sequencing/">Sanger sequencing</a> is &#x0003e;2% [Author, unpublished data]. With more sensitive methods such as <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>-specific <a class="def" href="/books/n/gene/glossary/def-item/pcr/">PCR</a> [<a class="bk_pop" href="#retinoblastoma.REF.rushlow.2009.842">Rushlow et al 2009</a>] or <a class="def" href="/books/n/gene/glossary/def-item/next-generation-sequencing/">next-generation sequencing</a> [<a class="bk_pop" href="#retinoblastoma.REF.chen.2014.384">Chen et al 2014</a>], parental mosaicism is detected in &#x0003e;4% of families.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with heritable retinoblastoma may appear to be negative because of failure to recognize the disorder in family members (retinoma), low-level <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a>, or reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with retinoblastoma has the disorder as the result of a somatic mosaic <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (i.e., a variant resulting from mutation that occurs in the proband during embryonic development), the parents do not have the pathogenic variant.</div></li><li class="half_rhythm"><div>Note: If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred, s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the variant and have fewer (unilateral) or no retinoblastomas.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to sibs of a proband depends on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and the genetic status of the parents:</p><ul><li class="half_rhythm"><div><b>Phenotype of the parents</b></div><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and the proband have bilateral retinoblastoma, the risk to the sibs is 50%. In rare families with "<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> low-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> retinoblastoma" the risk for tumor development in a sib with the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is reduced.</div></li><li class="half_rhythm"><div>When the parents are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low (i.e., 1%-2%; see <a class="figpopup" href="/books/NBK1452/table/retinoblastoma.T.empiric_risks_for_devel/?report=objectonly" target="object" rid-figpopup="figretinoblastomaTempiricrisksfordevel" rid-ob="figobretinoblastomaTempiricrisksfordevel">Table 3</a>). The sibs of a proband with clinically unaffected parents are still at increased risk for heritable retinoblastoma because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent or parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul></li><li class="half_rhythm"><div><b>Genetic status of the parents</b></div><ul><li class="half_rhythm"><div>If a parent is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, the risk to the sibs of inheriting the pathogenic variant is 50% and testing of sibs for the <i>RB1</i> pathogenic variant is warranted. In rare families with "<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> low-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> retinoblastoma" the risk for tumor development in a sib with the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variant is reduced.</div></li><li class="half_rhythm"><div>If the <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is low (&#x0003c; 5%) but greater than that of the general population because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. Thus, it is still recommended that each sib be tested for the <i>RB1</i> pathogenic variant identified in the proband; if the known <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> <i>RB1</i> pathogenic variant is not identified, the sib is "H0" [<a class="bk_pop" href="#retinoblastoma.REF.mallipatna.2017">Mallipatna et al 2017</a>, <a class="bk_pop" href="#retinoblastoma.REF.soliman.2017a.197">Soliman et al 2017a</a>, <a class="bk_pop" href="#retinoblastoma.REF.skalet.2018.453">Skalet et al 2018</a>].</div></li></ul></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> clearly shows <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for an <i>RB1</i> cancer-predisposing variant in non-cancer cells such as leukocyte DNA, it is assumed that the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> arose as a postzygotic event and that neither parent has an <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variant. The risk to the sibs is not increased and thus the testing of sibs for the <i>RB1</i> pathogenic variant identified in the proband is not warranted.</div></li><li class="half_rhythm"><div>If <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is not available or is uninformative, empiric risks based on tumor presentation (e.g., unifocal or multifocal) and family history can be used (<a class="figpopup" href="/books/NBK1452/table/retinoblastoma.T.empiric_risks_for_devel/?report=objectonly" target="object" rid-figpopup="figretinoblastomaTempiricrisksfordevel" rid-ob="figobretinoblastomaTempiricrisksfordevel">Table 3</a>) [<a class="bk_pop" href="#retinoblastoma.REF.skalet.2018.453">Skalet et al 2018</a>]. The low, but not negligible, risk to sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a negative family history presumably reflects the presence of either a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> with reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in one parent or <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> (that includes the germline) for an <i>RB1</i> pathogenic variant in one parent.</div></li><li class="half_rhythm"><div>If a parent has a cytogenetically detectable balanced <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 13 <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> or rearrangement, the sibs are at increased risk of inheriting an unbalanced chromosome rearrangement.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with heritable retinoblastoma has a 50% chance of inheriting the <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><ul><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has bilateral retinoblastoma and no family history of retinoblastoma, the presence of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> cancer-predisposing variant is assumed (H1) and the risk to each offspring of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is 50% [<a class="bk_pop" href="#retinoblastoma.REF.mallipatna.2017">Mallipatna et al 2017</a>]. Predictive DNA testing in offspring is possible if the cancer-predisposing <i>RB1</i> variant has been identified in the proband.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has had unilateral multifocal retinoblastoma and no family history of retinoblastoma, <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to offspring is lower [<a class="bk_pop" href="#retinoblastoma.REF.rushlow.2009.842">Rushlow et al 2009</a>].</div></li><li class="half_rhythm"><div>The risk to offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with unilateral unifocal disease and a negative family history is 6%, reflecting the possibility that the proband has <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> or a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>RB1</i> pathogenic variant associated with milder phenotypic expression. In families with "<a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> low-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> retinoblastoma" the risk for tumor development in persons with the low-penetrance <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is lower than the 95% observed with highly penetrant <i>RB1</i> "<a class="def" href="/books/n/gene/glossary/def-item/null/">null</a>" alleles.</div></li><li class="half_rhythm"><div>If the <i>RB1</i> pathogenic variants that have been detected in tumor tissue are not detected in DNA from leukocytes of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, there is an estimated 1.2% chance that the proband has <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> for one of the pathogenic variants identified in the tumor tissue. The offspring of the proband are at a 0.6% risk of inheriting a germline <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#retinoblastoma.REF.richter.2003.253">Richter et al 2003</a>]. Molecular genetic testing in offspring will check for both of the pathogenic variants identified in the tumor of the proband.</div></li><li class="half_rhythm"><div>If one of the pathogenic variants identified in the tumor is mosaic in DNA from leukocytes of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>, the level of <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> involvement is uncertain. All offspring should be checked for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in leukocyte DNA.</div></li></ul><div id="retinoblastoma.T.empiric_risks_for_devel" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Empiric Risks for Development of Retinoblastoma in Sibs and Offspring of a Proband when an <i>RB1</i> Germline Pathogenic Variant Has Not Been Identified</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1452/table/retinoblastoma.T.empiric_risks_for_devel/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__retinoblastoma.T.empiric_risks_for_devel_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Tumor Presentation in Index Case</th><th id="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_2" rowspan="3" scope="col" colspan="1" headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_2" style="text-align:left;vertical-align:middle;">Family<br />History</th><th id="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_3" rowspan="3" scope="col" colspan="1" headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_3" style="text-align:left;vertical-align:middle;">Risk to Sibs of<br />an Index Case</th><th id="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_4" rowspan="3" scope="col" colspan="1" headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_4" style="text-align:left;vertical-align:middle;">Risk to Offspring<br />of an Index Case</th></tr><tr><th headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_1" id="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_1" rowspan="2" scope="col" colspan="1" style="text-align:center;vertical-align:middle;">Bilateral</th><th headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1" id="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Unilateral</th></tr><tr><th headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2" id="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Multifocal</th><th headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2" id="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Unifocal</th></tr></thead><tbody><tr><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">X</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Negative</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2%&#x000a0;<sup>1</sup></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td></tr><tr><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">X</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Negative</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%-2%&#x000a0;<sup>1</sup></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6%-50%</td></tr><tr><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">X</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Negative</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~1%</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6%</td></tr><tr><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">X</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Positive</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variable&#x000a0;<sup>2</sup></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variable&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">X</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_1 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_2_2 hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Positive</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td><td headers="hd_h_retinoblastoma.T.empiric_risks_for_devel_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">50%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="retinoblastoma.TF.3.1"><p class="no_margin">If there is no unaffected sib [<a class="bk_pop" href="#retinoblastoma.REF.musarella.1987.124">Musarella &#x00026; Gallie 1987</a>, <a class="bk_pop" href="#retinoblastoma.REF.draper.1992.211">Draper et al 1992</a>, <a class="bk_pop" href="#retinoblastoma.REF.skalet.2018.453">Skalet et al 2018</a>]</p></div></dd><dt>2. </dt><dd><div id="retinoblastoma.TF.3.2"><p class="no_margin">In families with unilateral retinoblastoma, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> varies widely.</p></div></dd></dl></div></div></div><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, his or her family members may be at risk.</p></div><div id="retinoblastoma.Related_Genetic_Counselin"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#retinoblastoma.Evaluation_of_Relatives_a">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Predictive testing</b> for at-risk asymptomatic adult family members requires prior identification of the <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with heritable retinoblastoma has the pathogenic variant or clinical evidence of the disorder, the <i>RB1</i> pathogenic variant is likely to have arisen <i>de novo</i> [<a class="bk_pop" href="#retinoblastoma.REF.skalet.2018.453">Skalet et al 2018</a>]. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Genetic cancer risk assessment and counseling.</b> For a comprehensive description of the medical, psychosocial, and ethical ramifications of identifying at-risk individuals through cancer risk assessment with or without <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, see <a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cancer Genetics Risk Assessment and Counseling &#x02013; for health professionals</a> (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute).</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk [<a class="bk_pop" href="#retinoblastoma.REF.dommering.2012a.216">Dommering et al 2012a</a>].</div></li></ul><p><b>DNA banking</b> is the storage of DNA for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. If possible, DNA extracted from white blood cells and DNA extracted from tumor can be stored.</p></div><div id="retinoblastoma.Prenatal_Testing_and_Prei"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>When there is a family history of retinoblastoma, various options are available to optimize management of an at-risk pregnancy [<a class="bk_pop" href="#retinoblastoma.REF3">Canadian Retinoblastoma Society 2009</a>, <a class="bk_pop" href="#retinoblastoma.REF.soliman.2016.2610">Soliman et al 2016</a>]:</p><ul><li class="half_rhythm"><div>If the <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</div></li><li class="half_rhythm"><div>If an <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified in the fetus, ultrasound examination may be used to identify medium-sized intraocular tumors. If tumors are present, preterm delivery to enable early treatment may be considered [<a class="bk_pop" href="#retinoblastoma.REF.sahgal.2006.628">Sahgal et al 2006</a>]. Even if no tumors are visible on obstetric ultrasound, delivery of the fetus at 36 weeks' gestation may be recommended, as 30% of babies with an <i>RB1</i> pathogenic variant will have a tiny vision-threatening tumor [<a class="bk_pop" href="#retinoblastoma.REF.soliman.2016.2610">Soliman et al 2016</a>, <a class="bk_pop" href="#retinoblastoma.REF.soliman.2018.149">Soliman et al 2018</a>].</div></li><li class="half_rhythm"><div>If the <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has not been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal ultrasound or MRI may reveal a moderately large retinoblastoma in the eye of an affected fetus; however, these tests are not sensitive enough to detect small retinoblastoma tumors.</div></li></ul><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="retinoblastoma.Resources"><h2 id="_retinoblastoma_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Childhood Eye Cancer Trust (CHECT)</b></div><div>The Royal London Hospital</div><div>Whitechapel Road</div><div>London E1 1BB</div><div>United Kingdom</div><div><b>Phone:</b> +44 020 7377 5578</div><div><b>Fax:</b> +44 020 7377 0740</div><div><b>Email:</b> info@chect.org.uk</div><div><a href="https://chect.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.chect.org.uk</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Retinoblastoma&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Retinoblastoma</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/retinoblastoma" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Retinoblastoma</a></div></li><li class="half_rhythm"><div><b>National Retinoblastoma Parents Group</b></div><div>PO Box 317</div><div>Watertown MA 02471</div><div><b>Phone:</b> 800-562-6265</div><div><b>Fax:</b> 617-972-7444</div><div><b>Email:</b> napvi@perkins.pvt.k12.ma.us</div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22191/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Retinoblastoma</a></div></li><li class="half_rhythm"><div><b>World Eye Cancer Hope (WE C Hope)</b></div><div><a href="http://wechope.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.wechope.org</a></div></li><li class="half_rhythm"><div><b>American Childhood Cancer Organization (ACCO)</b></div><div>6868 Distribution Drive</div><div>Beltsville MD 20705</div><div><b>Phone:</b> 855-858-2226 (toll-free); 301-962-3520</div><div><b>Fax:</b> 301-962-3521</div><div><b>Email:</b> staff@acco.org</div><div><a href="http://www.acco.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.acco.org</a></div></li><li class="half_rhythm"><div><b>National Cancer Institute (NCI)</b></div><div>BG 9609 MSC 9760</div><div>9609 Medical Center Drive</div><div>Bethesda MD 20892-9760</div><div><b>Phone:</b> 800-4-CANCER</div><div><b>Email:</b> NCIinfo@nih.gov</div><div><a href="http://www.cancer.gov/publications/patient-education/children-with-cancer.pdf" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Children with Cancer: A Guide for Parents</a></div></li><li class="half_rhythm"><div><b>National Federation of the Blind (NFB)</b></div><div>200 East Wells Street</div><div>(at Jernigan Place)</div><div>Baltimore MD 21230</div><div><b>Phone:</b> 410-659-9314</div><div><b>Fax:</b> 410-685-5653</div><div><b>Email:</b> pmaurer@nfb.org</div><div><a href="http://www.nfb.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nfb.org</a></div></li><li class="half_rhythm"><div><b>eyeGENE - National Ophthalmic Disease Genotyping Network Registry</b></div><div><b>Phone:</b> 301-435-3032</div><div><b>Email:</b> eyeGENEinfo@nei.nih.gov</div><div><a href="https://eyegene.nih.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nei.nih.gov/eyegene</a></div></li></ul></div><div id="retinoblastoma.Molecular_Genetics"><h2 id="_retinoblastoma_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="retinoblastoma.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Retinoblastoma: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1452/table/retinoblastoma.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__retinoblastoma.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_retinoblastoma.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_retinoblastoma.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_retinoblastoma.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_retinoblastoma.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_retinoblastoma.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_retinoblastoma.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_retinoblastoma.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5925" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>RB1</i></a></td><td headers="hd_b_retinoblastoma.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5925" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">13q14<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_retinoblastoma.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P06400" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Retinoblastoma-associated protein</a></td><td headers="hd_b_retinoblastoma.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/RB1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RB1 database</a><br /><a href="http://rb1-lsdb.d-lohmann.de/home.php?select_db=RB1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rb1-lsdb</a></td><td headers="hd_b_retinoblastoma.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=RB1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RB1</a></td><td headers="hd_b_retinoblastoma.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=RB1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">RB1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="retinoblastoma.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="retinoblastoma.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Retinoblastoma (<a href="/omim/180200,614041" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1452/table/retinoblastoma.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__retinoblastoma.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/180200" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">180200</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RETINOBLASTOMA; RB1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614041" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614041</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RB TRANSCRIPTIONAL COREPRESSOR 1; RB1</td></tr></tbody></table></div></div><div id="retinoblastoma.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>With very rare exceptions, tumor development starts from cells that do not have a normal <i>RB1</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> [<a class="bk_pop" href="#retinoblastoma.REF.rushlow.2013.327">Rushlow et al 2013</a>]. See <a class="figpopup" href="/books/NBK1452/figure/retinoblastoma.F1/?report=objectonly" target="object" rid-figpopup="figretinoblastomaF1" rid-ob="figobretinoblastomaF1">Figure 1</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figretinoblastomaF1" co-legend-rid="figlgndretinoblastomaF1"><a href="/books/NBK1452/figure/retinoblastoma.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figretinoblastomaF1" rid-ob="figobretinoblastomaF1"><img class="small-thumb" src="/books/NBK1452/bin/retinoblastoma-Image001.gif" src-large="/books/NBK1452/bin/retinoblastoma-Image001.jpg" alt="Figure 1. . Schematic of the molecular genetic mechanisms that result in non-heritable and heritable retinoblastoma." /></a><div class="icnblk_cntnt" id="figlgndretinoblastomaF1"><h4 id="retinoblastoma.F1"><a href="/books/NBK1452/figure/retinoblastoma.F1/?report=objectonly" target="object" rid-ob="figobretinoblastomaF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Schematic of the molecular genetic mechanisms that result in non-heritable and heritable retinoblastoma. The development of retinoblastoma is initiated if both <i>RB1</i> alleles are mutated. In non-heritable retinoblastoma, both pathogenic variants (first and <a href="/books/NBK1452/figure/retinoblastoma.F1/?report=objectonly" target="object" rid-ob="figobretinoblastomaF1">(more...)</a></p></div></div><p><b>Gene structure.</b> Twenty-seven exons are transcribed and spliced into a 4.7-kb <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>. There is no indication of functional alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a>. A frequently used reference sequence for the transcript is <a href="/nuccore/NM_000321.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000321.2</a> (<a href="https://www.ncbi.nlm.nih.gov/clinvar/16453422/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LRG_517, t1</a>). For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1452/#retinoblastoma.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> No frequent benign variants within the 2.7-kb <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> are known, but there are <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> variants, two highly polymorphic microsatellites (Rb1.20, Rbi2), and one minisatellite (RBD).</p><p><b>Pathogenic variants.</b> More than 2,500 nucleotide variants have been observed in white blood cell DNA of individuals with retinoblastoma or in tumors; more than 1,700 are archived (see <a href="/books/NBK1452/#retinoblastoma.molgen.TA">Table A</a>, <b>Locus Specific</b>). The majority of <i>RB1</i> pathogenic variants result in a premature termination codon, usually through single-base substitutions, frameshift variants, or out-of-frame <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> skipping caused by <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants. Pathogenic variants have been found scattered throughout exon 1 to exon 25 of <i>RB1</i> and its <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a>. In a single family, a possible <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in exon 27 was identified [<a class="bk_pop" href="#retinoblastoma.REF.mitter.2009.55">Mitter et al 2009</a>]. Recurrent pathogenic variants are observed at methylated CpG dinucleotides that are part of CGA codons or the splice donor site of <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 12. Other important types of pathogenic variants are complex rearrangements and deletions [<a class="bk_pop" href="#retinoblastoma.REF.albrecht.2005.437">Albrecht et al 2005</a>, <a class="bk_pop" href="#retinoblastoma.REF.rushlow.2009.842">Rushlow et al 2009</a>, <a class="bk_pop" href="#retinoblastoma.REF.cast_ra.2013.460">Cast&#x000e9;ra et al 2013</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>RB1</i> encodes a ubiquitously expressed nuclear protein that is involved in cell cycle regulation (G1 to S transition). The RB protein is phosphorylated by members of the cyclin-dependent kinase (cdk) system prior to the entry into S-phase. On phosphorylation, the binding activity of the pocket <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> is lost, resulting in the release of cellular proteins. For a review see <a class="bk_pop" href="#retinoblastoma.REF.dick.2013.297">Dick &#x00026; Rubin [2013]</a>, <a class="bk_pop" href="#retinoblastoma.REF.dimaras.2015.15021">Dimaras et al [2015]</a> and <a class="bk_pop" href="#retinoblastoma.REF.dyson.2016.1492">Dyson [2016]</a>.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>RB1</i> lead to the expression of proteins that have lost cell cycle-regulating functions. Retention of partial activity has been observed in proteins resulting from pathogenic variants that are associated with low-<a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> retinoblastoma [<a class="bk_pop" href="#retinoblastoma.REF.bremner.1997.556">Bremner et al 1997</a>, <a class="bk_pop" href="#retinoblastoma.REF.otterson.1997.12036">Otterson et al 1997</a>, <a class="bk_pop" href="#retinoblastoma.REF.s_nchezs_nchez.2007.159">S&#x000e1;nchez-S&#x000e1;nchez et al 2007</a>].</p></div></div><div id="retinoblastoma.References"><h2 id="_retinoblastoma_References_">References</h2><div id="retinoblastoma.Published_Guidelines__Con"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF1">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <a href="http://jco.ascopubs.org/content/28/5/893.long" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 2-20-19.</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF2">American Society of Clinical Oncology. Statement on genetic testing for cancer susceptibility. 2003.</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF3">Canadian Retinoblastoma Society. National Retinoblastoma Strategy Canadian Guidelines for Care: Strat&#x000e9;gie th&#x000e9;rapeutique du r&#x000e9;tinoblastome guide clinique canadien. Available <a href="https://www.canadianjournalofophthalmology.ca/article/S0008-4182(09)80179-8/pdf" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2009. Accessed 2-20-19. [<a href="/pubmed/20237571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20237571</span></a>]</div></li></ul></div><div id="retinoblastoma.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.abouzeid.2009.771">Abouzeid H, Schorderet DF, Balmer A, Munier FL. Germline mutations in retinoma patients: relevance to low-penetrance and low-expressivity molecular basis. <span><span class="ref-journal">Mol Vis. </span>2009;<span class="ref-vol">15</span>:771–7.</span> [<a href="/pmc/articles/PMC2671583/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2671583</span></a>] [<a href="/pubmed/19390654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19390654</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.abramson.2003.1248">Abramson DH, Beaverson K, Sangani P, Vora RA, Lee TC, Hochberg HM, Kirszrot J, Ranjithan M. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. <span><span class="ref-journal">Pediatrics. </span>2003;<span class="ref-vol">112</span>:1248–55.</span> [<a href="/pubmed/14654593" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14654593</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.albrecht.2005.437">Albrecht P, Ansperger-Rescher B, Sch&#x000fc;ler A, Zeschnigk M, Gallie B, Lohmann DR. Spectrum of gross deletions and insertions in the RB1 gene in patients with retinoblastoma and association with phenotypic expression. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">26</span>:437–45.</span> [<a href="/pubmed/16127685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16127685</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF7">American Society of Clinical Oncology. Statement on genetic testing for cancer susceptibility. 2003.</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.bremner.1997.556">Bremner R, Du DC, Connolly-Wilson MJ, Bridge P, Ahmad KF, Mostachfi H, Rushlow D, Dunn JM, Gallie BL. Deletion of RB exons 24 and 25 causes low-penetrance retinoblastoma. <span><span class="ref-journal">Am J Hum Genet. </span>1997;<span class="ref-vol">61</span>:556–70.</span> [<a href="/pmc/articles/PMC1715941/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1715941</span></a>] [<a href="/pubmed/9326321" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9326321</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.canadian_retinoblastoma_society.2009.s1">Canadian Retinoblastoma Society.  National Retinoblastoma Strategy Canadian Guidelines for Care: Strat&#x000e9;gie th&#x000e9;rapeutique du r&#x000e9;tinoblastome guide clinique canadien. <span><span class="ref-journal">Can J Ophthalmol. </span>2009;<span class="ref-vol">44</span>:S1–88.</span> [<a href="/pubmed/20237571" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20237571</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.cast_ra.2013.460">Cast&#x000e9;ra L, Dehainault C, Michaux D, Lumbroso-Le Rouic L, Aerts I, Doz F, Pelet A, Couturier J, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C. Fine mapping of whole RB1 gene deletions in retinoblastoma patients confirms PCDH8 as a candidate gene for psychomotor delay. <span><span class="ref-journal">Eur J Hum Genet. </span>2013;<span class="ref-vol">21</span>:460–4.</span> [<a href="/pmc/articles/PMC3598316/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3598316</span></a>] [<a href="/pubmed/22909775" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22909775</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.chen.2014.384">Chen Z, Moran K, Richards-Yutz J, Toorens E, Gerhart D, Ganguly T, Shields CL, Ganguly A. Enhanced sensitivity for detection of low-level germline mosaic RB1 mutations in sporadic retinoblastoma cases using deep semiconductor sequencing. <span><span class="ref-journal">Hum Mutat. </span>2014;<span class="ref-vol">35</span>:384–91.</span> [<a href="/pmc/articles/PMC4112364/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4112364</span></a>] [<a href="/pubmed/24282159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24282159</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.de_jong.2014.1157">de Jong MC, Kors WA, de Graaf P, Castelijns JA, Kivela T, Moll AC. Trilateral retinoblastoma: a systematic review and meta-analysis. <span><span class="ref-journal">Lancet Oncol. </span>2014;<span class="ref-vol">15</span>:1157–67.</span> [<a href="/pubmed/25126964" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25126964</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.dehainault.2014.5243">Dehainault C, Garancher A, Cast&#x000e9;ra L, Cassoux N, Aerts I, Doz F, Desjardins L, Lumbroso L, Montes de Oca R, Almouzni G, Stoppa-Lyonnet D, Pouponnot C, Gauthier-Villars M, Houdayer C. The survival gene MED4 explains low penetrance retinoblastoma in patients with large RB1 deletion. <span><span class="ref-journal">Hum Mol Genet. </span>2014;<span class="ref-vol">23</span>:5243–50.</span> [<a href="/pubmed/24858910" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24858910</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.dick.2013.297">Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. <span><span class="ref-journal">Nat Rev Mol Cell Biol. </span>2013;<span class="ref-vol">14</span>:297–306.</span> [<a href="/pmc/articles/PMC4754300/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4754300</span></a>] [<a href="/pubmed/23594950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23594950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.dimaras.2015.15021">Dimaras H, Corson D, Cobrinik D, White A, Zhao J, Munier FL, Abramson DH, Shields CL, Chantada GL, Njuguna F, Gallie BL. Retinoblastoma. <span><span class="ref-journal">Nat Rev Dis Primers. </span>2015;<span class="ref-vol">1</span>:15021.</span> [<a href="/pmc/articles/PMC5744255/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5744255</span></a>] [<a href="/pubmed/27189421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27189421</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.dimaras.2008.1363">Dimaras H, Khetan V, Halliday W, Orlic M, Prigoda NL, Piovesan B, Marrano P, Corson TW, Eagle RC Jr, Squire JA, Gallie BL. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. <span><span class="ref-journal">Hum Mol Genet. </span>2008;<span class="ref-vol">17</span>:1363–72.</span> [<a href="/pubmed/18211953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18211953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.dommering.2012a.216">Dommering CJ, Garvelink MM, Moll AC, van Dijk J, Imhof SM, Meijers-Heijboer H, Henneman L. Reproductive behavior of individuals with increased risk of having a child with retinoblastoma. <span><span class="ref-journal">Clin Genet. </span>2012a;<span class="ref-vol">81</span>:216–23.</span> [<a href="/pubmed/21954974" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21954974</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.dommering.2012b.225">Dommering CJ, Marees T, van der Hout AH, Imhof SM, Meijers-Heijboer H, Ringens PJ, van Leeuwen FE, Moll AC. RB1 mutations and second primary malignancies after hereditary retinoblastoma. <span><span class="ref-journal">Fam Cancer. </span>2012b;<span class="ref-vol">11</span>:225–33.</span> [<a href="/pmc/articles/PMC3365233/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3365233</span></a>] [<a href="/pubmed/22205104" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22205104</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.dommering.2014.366">Dommering CJ, Mol BM, Moll AC, Burton M, Cloos J, Dorsman JC, Meijers-Heijboer H, van der Hout AH. RB1 mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients. <span><span class="ref-journal">J Med Genet. </span>2014;<span class="ref-vol">51</span>:366–74.</span> [<a href="/pubmed/24688104" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24688104</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.draper.1992.211">Draper GJ, Sanders BM, Brownbill PA, Hawkins MM. Patterns of risk of hereditary retinoblastoma and applications to genetic counselling. <span><span class="ref-journal">Br J Cancer. </span>1992;<span class="ref-vol">66</span>:211–9.</span> [<a href="/pmc/articles/PMC1977909/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1977909</span></a>] [<a href="/pubmed/1637670" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1637670</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.dyson.2016.1492">Dyson NJ. RB1: a prototype tumor suppressor and an enigma. <span><span class="ref-journal">Genes Dev. </span>2016;<span class="ref-vol">30</span>:1492–502.</span> [<a href="/pmc/articles/PMC4949322/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4949322</span></a>] [<a href="/pubmed/27401552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27401552</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.eloy.2016.e1005888">Eloy P, Dehainault C, Sefta M, Aerts I, Doz F, Cassoux N, Lumbroso le Rouic L, Stoppa-Lyonnet D, Radvanyi F, Millot GA, Gauthier-Villars M, Houdayer C. A parent-of-origin effect impacts the phenotype in low penetrance retinoblastoma families segregating the c.1981C&#x0003e;T/p.Arg661Trp mutation of RB1. <span><span class="ref-journal">PLoS Genet. </span>2016;<span class="ref-vol">12</span>:e1005888.</span> [<a href="/pmc/articles/PMC4771840/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4771840</span></a>] [<a href="/pubmed/26925970" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26925970</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.fletcher.2004.357">Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J. Lifetime risks of common cancers among retinoblastoma survivors. <span><span class="ref-journal">J Natl Cancer Inst. </span>2004;<span class="ref-vol">96</span>:357–63.</span> [<a href="/pubmed/14996857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14996857</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.frenkel.2016.313">Frenkel S, Zloto O, Sagi M, Fraenkel A, Pe'er J. Genotype-phenotype correlation in the presentation of retinoblastoma among 149 patients. <span><span class="ref-journal">Exp Eye Res. </span>2016;<span class="ref-vol">146</span>:313–7.</span> [<a href="/pubmed/27068507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27068507</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.imperatore.2018.1026">Imperatore V, Pinto AM, Gelli E, Trevisson E, Morbidoni V, Frullanti E, Hadjistilianou T, De Francesco S, Toti P, Gusson E, Roversi G, Accogli A, Capra V, Mencarelli MA, Renieri A, Ariani F. Parent-of-origin effect of hypomorphic pathogenic variants and somatic mosaicism impact on phenotypic expression of retinoblastoma. <span><span class="ref-journal">Eur J Hum Genet. </span>2018;<span class="ref-vol">26</span>:1026–37.</span> [<a href="/pmc/articles/PMC6018773/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6018773</span></a>] [<a href="/pubmed/29662154" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29662154</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.kleinerman.2007.24">Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE, Fraumeni JF Jr. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. <span><span class="ref-journal">J Natl Cancer Inst. </span>2007;<span class="ref-vol">99</span>:24–31.</span> [<a href="/pubmed/17202110" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17202110</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.kleinerman.2012.950">Kleinerman RA, Yu CL, Little MP, Li Y, Abramson D, Seddon J, Tucker MA. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. <span><span class="ref-journal">J Clin Oncol. </span>2012;<span class="ref-vol">30</span>:950–7.</span> [<a href="/pmc/articles/PMC3341108/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3341108</span></a>] [<a href="/pubmed/22355046" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22355046</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.klutz.2002.174">Klutz M, Brockmann D, Lohmann D. A parent-of-origin effect in two families with retinoblastoma is associated with a distinct splice mutation in the RB1 gene. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:174–9.</span> [<a href="/pmc/articles/PMC384976/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC384976</span></a>] [<a href="/pubmed/12016586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12016586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.maccarthy.2013.2455">MacCarthy A, Bayne AM, Brownbill PA, Bunch KJ, Diggens NL, Draper GJ, Hawkins MM, Jenkinson HC, Kingston JE, Stiller CA, Vincent TJ, Murphy MF. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. <span><span class="ref-journal">Br J Cancer. </span>2013;<span class="ref-vol">108</span>:2455–63.</span> [<a href="/pmc/articles/PMC3694232/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3694232</span></a>] [<a href="/pubmed/23674091" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23674091</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.mallipatna.2017">Mallipatna A, Gallie BL, Ch&#x000e9;vez-Barrios P, Lumbroso-Le Rouic L, Chantada GL, Doz F, et al. Retinoblastoma. In: Amin MB, Edge SB, Greene FL, eds. <em>AJCC Cancer Staging Manual</em>. 8 ed. New York, NY: Springer; 2017: 819-31.</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.marees.2008.1771">Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. <span><span class="ref-journal">J Natl Cancer Inst. </span>2008;<span class="ref-vol">100</span>:1771–9.</span> [<a href="/pubmed/19066271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19066271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.mitter.2009.55">Mitter D, Rushlow D, Nowak I, Ansperger-Rescher B, Gallie BL, Lohmann DR. Identification of a mutation in exon 27 of the RB1 gene associated with incomplete penetrance retinoblastoma. <span><span class="ref-journal">Fam Cancer. </span>2009;<span class="ref-vol">8</span>:55–8.</span> [<a href="/pubmed/18509746" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18509746</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.mitter.2011.947">Mitter D, Ullmann R, Muradyan A, Klein-Hitpass L, Kanber D, Ounap K, Kaulisch M, Lohmann D. Genotype-phenotype correlations in patients with retinoblastoma and interstitial 13q deletions. <span><span class="ref-journal">Eur J Hum Genet. </span>2011;<span class="ref-vol">19</span>:947–58.</span> [<a href="/pmc/articles/PMC3179359/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3179359</span></a>] [<a href="/pubmed/21505449" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21505449</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.moll.1997.559">Moll AC, Kuik DJ, Bouter LM, Den Otter W, Bezemer PD, Koten JW, Imhof SM, Kuyt BP, Tan KE. Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862-1995. <span><span class="ref-journal">Br J Ophthalmol. </span>1997;<span class="ref-vol">81</span>:559–62.</span> [<a href="/pmc/articles/PMC1722238/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1722238</span></a>] [<a href="/pubmed/9290369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9290369</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.musarella.1987.124">Musarella MA, Gallie BL. A simplified scheme for genetic counseling in retinoblastoma. <span><span class="ref-journal">J Pediatr Ophthalmol Strabismus. </span>1987;<span class="ref-vol">24</span>:124–5.</span> [<a href="/pubmed/3598831" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3598831</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.noorani.1996.301">Noorani HZ, Khan HN, Gallie BL, Detsky AS. Cost comparison of molecular versus conventional screening of relatives at risk for retinoblastoma. <span><span class="ref-journal">Am J Hum Genet. </span>1996;<span class="ref-vol">59</span>:301–7.</span> [<a href="/pmc/articles/PMC1914748/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1914748</span></a>] [<a href="/pubmed/8755916" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8755916</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.otterson.1997.12036">Otterson GA, Chen WD, Coxon AB, Khleif SN, Kaye FJ. Incomplete penetrance of familial retinoblastoma linked to germ-line mutations that result in partial loss of RB function. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>1997;<span class="ref-vol">94</span>:12036–40.</span> [<a href="/pmc/articles/PMC23695/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC23695</span></a>] [<a href="/pubmed/9342358" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9342358</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.richter.2003.253">Richter S, Vandezande K, Chen N, Zhang K, Sutherland J, Anderson J, Han L, Panton R, Branco P, Gallie B. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. <span><span class="ref-journal">Am J Hum Genet. </span>2003;<span class="ref-vol">72</span>:253–69.</span> [<a href="/pmc/articles/PMC379221/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC379221</span></a>] [<a href="/pubmed/12541220" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12541220</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.rushlow.2009.842">Rushlow D, Piovesan B, Zhang K, Prigoda-Lee NL, Marchong MN, Clark RD, Gallie BL. Detection of mosaic RB1 mutations in families with retinoblastoma. <span><span class="ref-journal">Hum Mutat. </span>2009;<span class="ref-vol">30</span>:842–51.</span> [<a href="/pubmed/19280657" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19280657</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.rushlow.2013.327">Rushlow DE, Mol BM, Kennett JY, Yee S, Pajovic S, Th&#x000e9;riault BL, Prigoda-Lee NL, Spencer C, Dimaras H, Corson TW, Pang R, Massey C, Godbout R, Jiang Z, Zacksenhaus E, Paton K, Moll AC, Houdayer C, Raizis A, Halliday W, Lam WL, Boutros PC, Lohmann D, Dorsman JC, Gallie BL. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. <span><span class="ref-journal">Lancet Oncol. </span>2013;<span class="ref-vol">14</span>:327–34.</span> [<a href="/pubmed/23498719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23498719</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.sahgal.2006.628">Sahgal A, Millar BA, Michaels H, Jaywant S, Chan HS, Heon E, Gallie B, Laperriere N. Focal stereotactic external beam radiotherapy as a vision-sparing method for the treatment of peripapillary and perimacular retinoblastoma: preliminary results. <span><span class="ref-journal">Clin Oncol (R Coll Radiol). </span>2006;<span class="ref-vol">18</span>:628–34.</span> [<a href="/pubmed/17051954" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17051954</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.s_nchezs_nchez.2007.159">S&#x000e1;nchez-S&#x000e1;nchez F, Ram&#x000ed;rez-Castillejo C, Weekes DB, Beneyto M, Prieto F, N&#x000e1;jera C, Mittnacht S. Attenuation of disease phenotype through alternative translation initiation in low-penetrance retinoblastoma. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:159–67.</span> [<a href="/pubmed/16988938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16988938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.seregard.2004.1228">Seregard S, Lundell G, Svedberg H, Kivel&#x000e4; T. Incidence of retinoblastoma from 1958 to 1998 in Northern Europe: advantages of birth cohort analysis. <span><span class="ref-journal">Ophthalmology. </span>2004;<span class="ref-vol">111</span>:1228–32.</span> [<a href="/pubmed/15177976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15177976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.skalet.2018.453">Skalet AH, Gombos DS, Gallie BL, Kim JW, Shields CL, Marr BP, Plon SE, Ch&#x000e9;vez-Barrios P. Screening children at risk for retinoblastoma: consensus report from the American Association of Ophthalmic Oncologists and Pathologists. <span><span class="ref-journal">Ophthalmology. </span>2018;<span class="ref-vol">125</span>:453–8.</span> [<a href="/pubmed/29056300" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29056300</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.soliman.2018.149">Soliman S, Kletke S, Roelofs K, VandenHoven C, McKeen L, Gallie B. Precision laser therapy for retinoblastoma. <span><span class="ref-journal">Expert Rev Ophthalmol. </span>2018;<span class="ref-vol">13</span>:149–59.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.soliman.2016.2610">Soliman SE, Dimaras H, Khetan V, Gardiner JA, Chan HS, H&#x000e9;on E, Gallie BL. Prenatal versus postnatal screening for familial retinoblastoma. <span><span class="ref-journal">Ophthalmology. </span>2016;<span class="ref-vol">123</span>:2610–7.</span> [<a href="/pubmed/27712844" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27712844</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.soliman.2017a.197">Soliman SE, Racher H, Zhang C, MacDonald H, Gallie BL. Genetics and molecular diagnostics in retinoblastoma--an update. <span><span class="ref-journal">Asia Pac J Ophthalmol (Phila). </span>2017a;<span class="ref-vol">6</span>:197–207.</span> [<a href="/pubmed/28399338" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28399338</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.soliman.2017b.859">Soliman SE, VandenHoven C, MacKeen LD, Heon E, Gallie BL. Optical coherence tomography-guided decisions in retinoblastoma management. <span><span class="ref-journal">Ophthalmology. </span>2017b;<span class="ref-vol">124</span>:859–72.</span> [<a href="/pubmed/28318638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28318638</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.taylor.2007.284">Taylor M, Dehainault C, Desjardins L, Doz F, Levy C, Sastre X, Couturier J, Stoppa-Lyonnet D, Houdayer C, Gauthier-Villars M. Genotype&#x02013;phenotype correlations in hereditary familial retinoblastoma. <span><span class="ref-journal">Hum Mutat. </span>2007;<span class="ref-vol">28</span>:284–93.</span> [<a href="/pubmed/17096365" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17096365</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.temming.2015.1799">Temming P, Viehmann A, Arendt M, Eisele L, Spix C, Bornfeld N, Sauerwein W, J&#x000f6;ckel KH, Lohmann DR. Pediatric second primary malignancies after retinoblastoma treatment. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2015;<span class="ref-vol">62</span>:1799–804.</span> [<a href="/pubmed/25970657" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25970657</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.temming.2013.475">Temming P, Viehmann A, Biewald E, Lohmann DR. Sporadic unilateral retinoblastoma or first sign of bilateral disease? <span><span class="ref-journal">Br J Ophthalmol. </span>2013;<span class="ref-vol">97</span>:475–80.</span> [<a href="/pubmed/23355526" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23355526</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.valverde.2002.277">Valverde K, Pandya J, Heon E, Goh TS, Gallie BL, Chan HS. Retinoblastoma with central retinal artery thrombosis that mimics extraocular disease. <span><span class="ref-journal">Med Pediatr Oncol. </span>2002;<span class="ref-vol">38</span>:277–9.</span> [<a href="/pubmed/11920797" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11920797</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.wong.1997.1262">Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MB, Seddon JM, Tarbell N, Fraumeni JF Jr, Li FP. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. <span><span class="ref-journal">JAMA. </span>1997;<span class="ref-vol">278</span>:1262–7.</span> [<a href="/pubmed/9333268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9333268</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="retinoblastoma.REF.zeschnigk.2004.e125">Zeschnigk M, B&#x000f6;hringer S, Price EA, Onadim Z, Massh&#x000f6;fer L, Lohmann DR. A novel real-time PCR assay for quantitative analysis of methylated alleles (QAMA): analysis of the retinoblastoma locus. <span><span class="ref-journal">Nucleic Acids Res. </span>2004;<span class="ref-vol">32</span>:e125.</span> [<a href="/pmc/articles/PMC519124/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC519124</span></a>] [<a href="/pubmed/15353561" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15353561</span></a>]</div></li></ul></div></div><div id="retinoblastoma.Chapter_Notes"><h2 id="_retinoblastoma_Chapter_Notes_">Chapter Notes</h2><div id="retinoblastoma.Author_History"><h3>Author History</h3><p>Norbert Bornfeld, MD; University of Essen (2000-2004)<br />Brenda L Gallie, MD (2004-present)<br />Bernhard Horsthemke, PhD; University of Essen (2000-2004)<br />Dietmar R Lohmann, MD (2000-present)<br />Eberhard Passarge, MD; University of Essen (2000-2004)</p></div><div id="retinoblastoma.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>21 November 2018 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 November 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 March 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>10 June 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 May 2007 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 January 2005 (dl) Revision: Risk to offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></div></li><li class="half_rhythm"><div>28 December 2004 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 January 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 July 2000 (me) Review posted live</div></li><li class="half_rhythm"><div>21 January 1999 (dl) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1452</span><span class="label">PMID: <a href="/pubmed/20301625" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301625</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/rvcl/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/rtps/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1452&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1452/?report=reader">PubReader</a></li><li><a href="/books/NBK1452/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1452" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1452" style="display:none" title="Cite this Page"><div class="bk_tt">Lohmann DR, Gallie BL. Retinoblastoma. 2000 Jul 18 [Updated 2018 Nov 21]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1452/pdf/Bookshelf_NBK1452.pdf">PDF version of this page</a> (595K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#retinoblastoma.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#retinoblastoma.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#retinoblastoma.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#retinoblastoma.Genetically_Related_Allel" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#retinoblastoma.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#retinoblastoma.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#retinoblastoma.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#retinoblastoma.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#retinoblastoma.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#retinoblastoma.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#retinoblastoma.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5925[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">RB1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1496386" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1496386" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1496386" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1496386" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301488" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schneider K, Zelley K, Nichols KE, Garber J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301575" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mehta PA, Tolar J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301534" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PAX6</i>-Related Aniridia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PAX6</i>-Related Aniridia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Moosajee M, Hingorani M, Moore AT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29215836" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Rhabdoid Tumor Predisposition Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Rhabdoid Tumor Predisposition Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nemes K, Bens S, Bourdeaut F, Hasselblatt M, Kool M, Johann P, Kordes U, Schneppenheim R, Siebert R, Frühwald MC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301744" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CDC73</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CDC73</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hyde SM, Rich TA, Waguespack SG, Perrier ND, Hu MI. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301625" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301625" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0415d875f66d18aa52a61f">Retinoblastoma - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Retinoblastoma - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:07:20-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A0D26E0404AA10000000007360292&amp;ncbi_session=CE8A0D26E0415D71_1846SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1452%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1452&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1452/&amp;ncbi_pagename=Retinoblastoma - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A0D26E0415D71_1846SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>